'Mad Money' Uncover...
Health Care: Drugs
AcelRx Pharmaceuticals Inc. (ACRX: NASDAQ)
$6.71 0.25 | 3.87%
05/21/13 - 01:11 PM ET
Portfolios with ACRX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Under-$10 Moving Hig...
Latest ACRX Headlines from TheStreet
- 4 Biotech Stocks Under $10 Making Big Moves 04.09.13 | 02:04 pm
- 5 Stocks Poised for Breakouts 02.01.13 | 01:02 pm
- 5 Stocks Insiders Are Stuffing in Their Stockings 12.12.12 | 12:12 pm
- Dunkin' Brands Prices IPO Above Range 07.26.11 | 07:07 pm
- IPO Lessons From Pandora 02.16.11 | 01:02 pm
- IPO Watch: 2011 02.16.11 | 01:02 pm
- Gaskins Warns on Speculative Pharma IPOs
02.02.11 | 08:02 am
Press Releases for ACRX
- AcelRx Pharmaceuticals To Present At The UBS Global Healthcare Conference - PR Newswire 05.16.13 | 03:05 pm
- AcelRx Pharmaceuticals To Hold First Quarter 2013 Financial Results Conference Call And Webcast On May 8, 2013 - PR Newswire 05.03.13 | 07:05 am
- AcelRx Pharmaceuticals Presents Positive Clinical Data For The Sufentanil NanoTab PCA System At ASRA Medical Meeting - PR Newswire 05.02.13 | 07:05 am
- Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint In Dose-Finding Phase 2 Clinical Trial - PR Newswire 04.24.13 | 07:04 am
- AcelRx Pharmaceuticals To Hold Fourth Quarter 2012 Financial Results Conference Call And Webcast On March 12, 2013 - PR Newswire 03.07.13 | 07:03 am
- AcelRx Top-line Data Show Primary Endpoint Achieved In Pivotal Phase 3 Study Of Sufentanil NanoTab PCA System For Post-Operative Pain In Major Open Abdominal Surgery Patients - PR Newswire 03.04.13 | 06:03 pm
- AcelRx Pharmaceuticals To Present At Two Upcoming Investor Conferences - PR Newswire 02.27.13 | 07:02 am
- AcelRx Pharmaceuticals Provides Clinical Trial Updates - PR Newswire 02.19.13 | 07:02 am
- AcelRx Appoints Adrian Adams To Board Of Directors As Chairman - PR Newswire 02.12.13 | 07:02 am
- AcelRx Pharmaceuticals Announces Exercise Of Option To Purchase Additional Shares - PR Newswire 12.14.12 | 12:12 pm
Partner Headlines for ACRX
- Pre-Market Most Active for May 21, 2013 : JASO, MSFT, SDBT, AMAT, ACRX, CSIQ - NASDAQ 05.21.13 | 12:05 pm
- UPDATE: Jefferies Initiates AcelRx Pharmaceuticals with Buy on Expected FDA Approval for ARX-01 - Benzinga 04.08.13 | 09:04 am
- After-Hours Earnings Report for March 12, 2013 : KW, DOLE, ACAD, GCA, GNMK, AVID, WSR, KTOS, GERN, ACRX, FOLD, GCAP - NASDAQ 03.12.13 | 06:03 pm
- AcelRx Pharma: Pain Drug Developer With A Pair Of Q1 2013 Phase III Catalysts - Seeking Alpha 12.22.12 | 09:12 am
- FROM EARLIER: AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab® PCA System vs. IV PCA Morphine for Post-Operative Pain - Benzinga 11.15.12 | 08:11 am
- New IPO Filings And What's On The Horizon - Seeking Alpha 02.03.12 | 06:02 pm
- Company News for May 27, 2011 - Corporate Summary - Zacks 05.27.11 | 10:05 am
